Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Autolus Therapeutics Reports 42.6-Month Median Response From FELIX Study, Showing Obe-Cel's Potential For Long-Term Remission In r/r B-ALL

Author: Benzinga Newsdesk | June 12, 2025 02:33am
  • Median duration of response in FELIX study now 42.6 months after an additional 11 months of follow up
  • More than half of patients still in remission at 24 months
  • 38% of ongoing responders did not receive any subsequent therapy by month 33
  • Results suggest a proportion of patients with r/r B-ALL may not need further therapy following treatment with obe-cel

Posted In: AUTL


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist